FDA's Initiatives Will Not Be Affected By Election Results, Crawford Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Efforts to develop guidance on pharmacogenomics and combination Rx/Dx products are "progress in the making" and not vulnerable to changes in political leadership, FDA Acting Commissioner Crawford maintains.